3 Turnaround Candidates for 2018 You Should Consider Now

Beleaguered companies such as Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) and others could stand to finally see a turnaround in 2018.

| More on:

Everyone loves a comeback story.

The market is full of them, and it’s during this end-of-year frenzy, between turkey dinners with family, that investors look towards next year and determine if some former greats could turn around.

Here are a few options to consider moving into 2018.

There’s no better stock that comes to mind when thinking of “epic collapse” than Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX). The former darling of the market once had a market cap that exceeded some of Canada’s big banks before tumbling over 90% two years ago.

There are multiple reasons for that epic collapse, but a big one was that Valeant had a flawed business model that was overly reliant on cheap debt. When the stock finally tanked, Valeant was left with a broken business model, over US$30 billion in debt, and a stock price that left investors shaking their heads in disbelief.

Why is Valeant a good option now? Valeant’s new management team, headed by CEO Joseph Papa has not only begun to clean up the mess left by others, but it’s using a proper business model that is not entirely fueled on cheap loans. The company has also aggressively focused on debt reduction, selling non-core assets to pay down the mountain of debt.

Valeant is on track to finish 2017 on an impressive run with a stock price that is up year to date by 40%.

Cameco Corp. (TSX:CCO)(NYSE:CCJ) is another interesting turnaround target that is beginning to gain steam. Cameco is one of the largest uranium miners in the world, providing fuel for nuclear power plants.

The problem with Cameco is that when the Fukushima reactor in Japan was damaged following an earthquake-induced tsunami in 2011, world demand for uranium effectively dried up. This left Cameco and other uranium miners extracting uranium (for a significant cost) that nobody was buying. As the price continued to drop, and supplies continued to increase, a glut was formed that kept prices low, which was, thankfully, not entirely felt by Cameco due to the nature of long-term uranium purchase agreements.

There are two reasons to be optimistic about Cameco in 2018. First, Cameco and other leading uranium miners have announced a series of significant production cuts recently that will clear the supply glut and hopefully see prices begin to rise. The second reason has to do with demand, which is steadily growing thanks to a flurry of new construction and infrastructure development across the developing nations of Asia.

BlackBerry Ltd. (TSX:BB)(NYSE:BB) is another perennial turnaround candidate, which is arguably in the latter phases of its transformation. The company once had the leading market share of smartphones around the world, at least until both Android and iOS gobbled up that market share and reduced BlackBerry’s usage to little more than a rounding error.

Today, the company has little in common with its former self apart from a strong desire and industry-leading knowledge on security. BlackBerry no longer makes devices itself; rather, it licenses third parties to manufacture and market the devices.

BlackBerry’s real potential in 2018 and beyond lies in another area: automation. The company’s IoT asset-tracking solution holds promise, and the brain behind BlackBerry’s failed proprietary BB10 platform, QNX, is a key component to the future of autonomous driving; it’s already installed in over 60 million vehicles worldwide.

Year to date, BlackBerry has soared nearly 60%, and 2018 looks to be even more promising, as the company has finally returned to profitability.

Fool contributor Demetris Afxentiou has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of BlackBerry and Valeant Pharmaceuticals. BlackBerry is a recommendation of Stock Advisor Canada.

More on Tech Stocks

A doctor takes a patient's blood pressure in a clinical office.
Tech Stocks

Wake Up Canadian Investors: If You’re Not Doing This You’re Probably Using Your TFSA All Wrong

Your TFSA is a tax-free wealth machine — but only if you use it right. Here's why Tecsys stock could…

Read more »

A robotic hand interacting with a visual AI touchscreen display.
Tech Stocks

1 Growth Stock Set to Skyrocket in 2026 and Beyond

Tracking Kraken Robotics (TSXV:PNG) stock? Its $615 million acquisition and the NATO defence boom could turn this marine tech leader…

Read more »

chart reflected in eyeglass lenses
Tech Stocks

This Canadian Stock Is Down 50% and Nearly Perfect for Long-Term Investors

Kits Eyecare stock is down 50% from its highs, but 14 straight quarters of 20%-plus revenue growth tell a very…

Read more »

visualization of a digital brain
Tech Stocks

2 Canadian Stocks Primed to Surge in 2026

Given their solid financial growth and healthy growth prospects, these two Canadian stocks offer attractive buying opportunities.

Read more »

young adult uses credit card to shop online
Tech Stocks

Lightspeed Stock Just Quietly Made One of Its Biggest Moves in Years

Lightspeed may have sold off after earnings, but its CEO says the real story is a pivot to “profitable growth.”

Read more »

sovereign AI stocks in canada
Tech Stocks

3 Stocks for Canada’s $9 Billion AI Bet

Canada is making a massive push to build its own AI infrastructure — and investors will probably want to take…

Read more »

young people dance to exercise
Tech Stocks

Why I’m Buying This ETF Like There’s No Tomorrow and Never Selling 

Explore why ETFs are a smart choice for investing. Simplify your strategy and let your money grow with indexed funds.

Read more »

A data center engineer works on a laptop at a server farm.
Tech Stocks

2 Canadian Crypto Stocks I’d Avoid (and 1 I’d Buy Instead)

Crypto-to-AI pivots sound exciting, but the safer way to play the boom might be a proven AI supplier like Celestica.

Read more »